ARCHIVES

Report Criticizes NIH Grant Review

This article is from The Cancer Letter archive.

Vol. 21 No. 24 | June 16, 1995

Download PDF Visit The Full Archive

Related Articles

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

March 29, 2013

NLST Suggests 18.5 Percent Of LDCT-Detected Cancers Could Be Indolent

December 27, 2013

Controversy Continues, Scientists, Advocates, Clinicians Say

January 31, 1997

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

October 3, 2014

Concepts Approved For New Technology In Computers, Recompetition

November 6, 1987

Guest Editorial: MD Anderson’s Judith Smith Questions NCI Short-Term Remedy For Carboplatin Dosing

October 15, 2010